世界のB細胞成熟抗原（BCMA）標的療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3893 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、B細胞成熟抗原（BCMA）標的療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（二重特異性抗体、抗体薬物複合体、キメラ抗原受容体T細胞）、用途別市場規模（肝臓がん、呼吸器がん、脳腫瘍、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・B細胞成熟抗原（BCMA）標的療法の市場動向 ・企業の競争状況、市場シェア ・B細胞成熟抗原（BCMA）標的療法の種類別市場規模と予測2016-2027（二重特異性抗体、抗体薬物複合体、キメラ抗原受容体T細胞） ・B細胞成熟抗原（BCMA）標的療法の用途別市場規模と予測2016-2027（肝臓がん、呼吸器がん、脳腫瘍、その他） ・B細胞成熟抗原（BCMA）標的療法の北米市場規模2016-2027（アメリカ、カナダ） ・B細胞成熟抗原（BCMA）標的療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・B細胞成熟抗原（BCMA）標的療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・B細胞成熟抗原（BCMA）標的療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・B細胞成熟抗原（BCMA）標的療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Transposagen Biopharmaceuticals、Sutro Biopharma、Malin Corporation、Eureka Therapeutics、firstVentury Equity、Five Prime Therapeutics、Credit Suisse Securities、Dana-Farber Cancer Institute、Deerfield Partners、Onyx Pharmaceuticals、Juno Therapeutics） ・結論

Market Analysis and Insights: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
The global B-Cell Maturation Antigen(BCMA) Targeted Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market.

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Scope and Market Size
B-Cell Maturation Antigen(BCMA) Targeted Therapies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells

Segment by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Bispecific Antibodies
1.2.3 Antibody Drug Conjugates
1.2.4 Chimeric Antigen Receptor T-Cells
1.3 Market by Application
1.3.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Perspective (2016-2027)
2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Trends by Regions
2.2.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Share by Regions (2016-2021)
2.2.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Regions (2022-2027)
2.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Dynamic
2.3.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Trends
2.3.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Drivers
2.3.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Challenges
2.3.4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Revenue
3.1.1 Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Revenue (2016-2021)
3.1.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Players (2016-2021)
3.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue
3.4 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Ratio
3.4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue in 2020
3.5 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players Head office and Area Served
3.6 Key Players B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Solution and Service
3.7 Date of Enter into B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Breakdown Data by Type
4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Type (2016-2021)
4.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Type (2022-2027)

5 B-Cell Maturation Antigen(BCMA) Targeted Therapies Breakdown Data by Application
5.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Application (2016-2021)
5.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
6.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type
6.2.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021)
6.2.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027)
6.2.3 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2027)
6.3 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application
6.3.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021)
6.3.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027)
6.3.3 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2027)
6.4 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country
6.4.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021)
6.4.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
7.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type
7.2.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021)
7.2.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027)
7.2.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2027)
7.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application
7.3.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021)
7.3.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027)
7.3.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2027)
7.4 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country
7.4.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021)
7.4.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
8.2 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type
8.2.1 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2027)
8.3 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application
8.3.1 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2027)
8.4 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region
8.4.1 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
9.2 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type
9.2.1 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021)
9.2.2 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027)
9.2.3 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2027)
9.3 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application
9.3.1 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021)
9.3.2 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027)
9.3.3 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2027)
9.4 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country
9.4.1 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021)
9.4.2 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
10.2 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type
10.2.1 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2027)
10.3 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application
10.3.1 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2027)
10.4 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country
10.4.1 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Transposagen Biopharmaceuticals
11.1.1 Transposagen Biopharmaceuticals Company Details
11.1.2 Transposagen Biopharmaceuticals Business Overview
11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.1.5 Transposagen Biopharmaceuticals Recent Development
11.2 Sutro Biopharma
11.2.1 Sutro Biopharma Company Details
11.2.2 Sutro Biopharma Business Overview
11.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.2.5 Sutro Biopharma Recent Development
11.3 Malin Corporation
11.3.1 Malin Corporation Company Details
11.3.2 Malin Corporation Business Overview
11.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.3.5 Malin Corporation Recent Development
11.4 Eureka Therapeutics
11.4.1 Eureka Therapeutics Company Details
11.4.2 Eureka Therapeutics Business Overview
11.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.4.5 Eureka Therapeutics Recent Development
11.5 firstVentury Equity
11.5.1 firstVentury Equity Company Details
11.5.2 firstVentury Equity Business Overview
11.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.5.5 firstVentury Equity Recent Development
11.6 Five Prime Therapeutics
11.6.1 Five Prime Therapeutics Company Details
11.6.2 Five Prime Therapeutics Business Overview
11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.6.5 Five Prime Therapeutics Recent Development
11.7 Credit Suisse Securities
11.7.1 Credit Suisse Securities Company Details
11.7.2 Credit Suisse Securities Business Overview
11.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.7.5 Credit Suisse Securities Recent Development
11.8 Dana-Farber Cancer Institute
11.8.1 Dana-Farber Cancer Institute Company Details
11.8.2 Dana-Farber Cancer Institute Business Overview
11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.8.5 Dana-Farber Cancer Institute Recent Development
11.9 Deerfield Partners
11.9.1 Deerfield Partners Company Details
11.9.2 Deerfield Partners Business Overview
11.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.9.5 Deerfield Partners Recent Development
11.10 Onyx Pharmaceuticals
11.10.1 Onyx Pharmaceuticals Company Details
11.10.2 Onyx Pharmaceuticals Business Overview
11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.10.5 Onyx Pharmaceuticals Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Details
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
11.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
11.11.5 Juno Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Bispecific Antibodies
Table 3. Key Players of Antibody Drug Conjugates
Table 4. Key Players of Chimeric Antigen Receptor T-Cells
Table 5. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Regions (2016-2021)
Table 9. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Regions (2022-2027)
Table 11. B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Trends
Table 12. B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Drivers
Table 13. B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Challenges
Table 14. B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Restraints
Table 15. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Players (2016-2021)
Table 17. Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies as of 2020)
Table 18. Ranking of Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Solution and Service
Table 22. Date of Enter into B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 25. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type (2016-2021)
Table 26. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Application (2016-2021)
Table 30. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 33. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021) (US$ Million)
Table 35. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 62. Transposagen Biopharmaceuticals Company Details
Table 63. Transposagen Biopharmaceuticals Business Overview
Table 64. Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 65. Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 66. Transposagen Biopharmaceuticals Recent Development
Table 67. Sutro Biopharma Company Details
Table 68. Sutro Biopharma Business Overview
Table 69. Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 70. Sutro Biopharma Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 71. Sutro Biopharma Recent Development
Table 72. Malin Corporation Company Details
Table 73. Malin Corporation Business Overview
Table 74. Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 75. Malin Corporation Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 76. Malin Corporation Recent Development
Table 77. Eureka Therapeutics Company Details
Table 78. Eureka Therapeutics Business Overview
Table 79. Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 80. Eureka Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 81. Eureka Therapeutics Recent Development
Table 82. firstVentury Equity Company Details
Table 83. firstVentury Equity Business Overview
Table 84. firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 85. firstVentury Equity Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 86. firstVentury Equity Recent Development
Table 87. Five Prime Therapeutics Company Details
Table 88. Five Prime Therapeutics Business Overview
Table 89. Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 90. Five Prime Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 91. Five Prime Therapeutics Recent Development
Table 92. Credit Suisse Securities Company Details
Table 93. Credit Suisse Securities Business Overview
Table 94. Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 95. Credit Suisse Securities Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 96. Credit Suisse Securities Recent Development
Table 97. Dana-Farber Cancer Institute Company Details
Table 98. Dana-Farber Cancer Institute Business Overview
Table 99. Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 100. Dana-Farber Cancer Institute Recent Development
Table 101. Deerfield Partners Company Details
Table 102. Deerfield Partners Business Overview
Table 103. Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 104. Deerfield Partners Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 105. Deerfield Partners Recent Development
Table 106. Onyx Pharmaceuticals Company Details
Table 107. Onyx Pharmaceuticals Business Overview
Table 108. Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 109. Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 110. Onyx Pharmaceuticals Recent Development
Table 111. Juno Therapeutics Company Details
Table 112. Juno Therapeutics Business Overview
Table 113. Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
Table 114. Juno Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021) & (US$ Million)
Table 115. Juno Therapeutics Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type: 2020 VS 2027
Figure 2. Bispecific Antibodies Features
Figure 3. Antibody Drug Conjugates Features
Figure 4. Chimeric Antigen Receptor T-Cells Features
Figure 5. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application: 2020 VS 2027
Figure 6. Liver Cancer Case Studies
Figure 7. Respiratory Cancer Case Studies
Figure 8. Brain Cancer Case Studies
Figure 9. Others Case Studies
Figure 10. B-Cell Maturation Antigen(BCMA) Targeted Therapies Report Years Considered
Figure 11. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Regions: 2020 VS 2027
Figure 14. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Regions (2022-2027)
Figure 15. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Players in 2020
Figure 16. Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies as of 2020
Figure 17. The Top 10 and 5 Players Market Share by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue in 2020
Figure 18. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type (2016-2021)
Figure 19. Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Type (2022-2027)
Figure 20. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2016-2027)
Figure 22. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2016-2027)
Figure 23. North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Country (2016-2027)
Figure 24. United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2016-2027)
Figure 28. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2016-2027)
Figure 29. Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Country (2016-2027)
Figure 30. Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2016-2027)
Figure 38. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2016-2027)
Figure 39. Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Region (2016-2027)
Figure 40. China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2016-2027)
Figure 48. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2016-2027)
Figure 49. Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Country (2016-2027)
Figure 50. Mexico B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2016-2027)
Figure 54. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2016-2027)
Figure 55. Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Country (2016-2027)
Figure 56. Turkey B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Transposagen Biopharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 60. Sutro Biopharma Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 61. Malin Corporation Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 62. Eureka Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 63. firstVentury Equity Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 64. Five Prime Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 65. Credit Suisse Securities Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 66. Dana-Farber Cancer Institute Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 67. Deerfield Partners Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 68. Onyx Pharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 69. Juno Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---